No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Approval Alert: FDA Approves Boehringer Ingelheim’s High-Concentration, Citrate-Free Humira® Formulation of Cyltezo®, Biosimilar
On 01 May 2024, Boehringer Ingelheim announced that the FDA approved its high-concentration, citrate-free formulation of Cyltezo® (biosimilar to Abbvie's Humira® (adalimumab)), for multiple chronic inflammatory diseases. BI now has approvals for the high (100 mg/mL)...